Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Assetmark Inc.

Assetmark Inc. lessened its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 2.9% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 100,975 shares of the biopharmaceutical company's stock after selling 3,005 shares during the period. Assetmark Inc. owned 0.09% of Regeneron Pharmaceuticals worth $71,927,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Proficio Capital Partners LLC increased its stake in shares of Regeneron Pharmaceuticals by 92,865.3% in the fourth quarter. Proficio Capital Partners LLC now owns 219,398 shares of the biopharmaceutical company's stock worth $156,284,000 after purchasing an additional 219,162 shares in the last quarter. Worldquant Millennium Advisors LLC purchased a new stake in Regeneron Pharmaceuticals in the 3rd quarter worth $127,489,000. KBC Group NV raised its holdings in Regeneron Pharmaceuticals by 296.7% during the fourth quarter. KBC Group NV now owns 136,647 shares of the biopharmaceutical company's stock valued at $97,338,000 after acquiring an additional 102,198 shares during the period. Icon Wealth Advisors LLC lifted its position in shares of Regeneron Pharmaceuticals by 18,342.0% in the third quarter. Icon Wealth Advisors LLC now owns 75,981 shares of the biopharmaceutical company's stock valued at $79,874,000 after acquiring an additional 75,569 shares in the last quarter. Finally, State Street Corp boosted its stake in shares of Regeneron Pharmaceuticals by 1.3% in the third quarter. State Street Corp now owns 4,902,404 shares of the biopharmaceutical company's stock worth $5,153,603,000 after acquiring an additional 61,277 shares during the period. Hedge funds and other institutional investors own 83.31% of the company's stock.

Wall Street Analyst Weigh In

A number of research analysts recently commented on the company. Oppenheimer lowered their price target on Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an "outperform" rating on the stock in a report on Wednesday, November 6th. Bank of America reissued an "underperform" rating and issued a $565.00 target price on shares of Regeneron Pharmaceuticals in a report on Tuesday, December 10th. Citigroup cut their target price on shares of Regeneron Pharmaceuticals from $795.00 to $750.00 and set a "neutral" rating for the company in a research note on Tuesday, January 28th. Piper Sandler decreased their price target on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a research note on Monday, January 27th. Finally, Canaccord Genuity Group lowered Regeneron Pharmaceuticals from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, December 17th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average target price of $973.13.

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN traded up $11.66 during mid-day trading on Wednesday, reaching $687.15. 828,674 shares of the stock were exchanged, compared to its average volume of 608,258. The company has a market capitalization of $75.12 billion, a P/E ratio of 17.95, a P/E/G ratio of 2.34 and a beta of 0.08. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73. The business's 50 day moving average is $696.58 and its 200-day moving average is $857.92. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last posted its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same period in the prior year, the company posted $11.86 EPS. The company's revenue for the quarter was up 10.3% on a year-over-year basis. On average, equities research analysts forecast that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current fiscal year.

Regeneron Pharmaceuticals Announces Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be given a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.51%. The ex-dividend date of this dividend is Thursday, February 20th. Regeneron Pharmaceuticals's dividend payout ratio (DPR) is presently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.